26 Apr Smith+Nephew expands sports medicine wireless arthroscopic tower with new fluid management and 4K surgical imaging technology
Designed to be simple, effective and connected, the DOUBLEFLO Pump** is able to respond to a surgeon’s needs in diverse clinical situations1,2. It can be controlled remotely by the LENS Connected Tower App*** and offers heads-up display projection on the arthroscopic tower, allowing surgeons to focus on the patient rather than equipment.
The new line of 4KO Scopes**** expands Smith+Nephew’s 4K surgical imaging portfolio for multi-specialty centers. Designed with improved image quality, the 4KO Direct View Arthroscopes have a 30% minimum increase in resolution compared to Smith+Nephew HD DV arthroscopes3. And by offering C-mount and Direct View coupling, surgeons have the flexibility to choose the scope that works best for them based on procedure type and surgical preference.
Introduced last year, the INTELLIO Connected Tower provides sports medicine surgeons with a complete suite of enabling technologies in the operating room. It uses a centralized app to wirelessly connect and control the major components of an arthroscopy surgical tower from outside the sterile field, helping to streamline procedure support.
“Smith+Nephew’s new 4KO Arthroscopes provide increased brightness and clarity in the hip space allowing me to better diagnose the integrity of the labrum and associated anatomy when determining how to best treat my patients,” said Dr. Benjamin Petre, Orthopaedic Surgeon and Medical Director of Sports Medicine for Luminis Health System in Annapolis, Maryland.
“Smith+Nephew continues to expand its portfolio of Arthroscopic Enabling Technologies to help customers maximize the value of their capital investments,” said Scott Schaffner, SVP of Global Marketing and US Commercial, Sports Medicine at Smith+Nephew. “The DOUBLEFLO Pump and 4KO Scopes represent the latest advancements designed to bring world-class performance to the surgical tower.”
The DOUBLEFLO Pump and 4KO Scopes are available now in both the US and Europe.
- Hemodia 2020.Verification Test Report – Response Time After Volume Modification. Internal Report. HP3-RAP-053-B.
- Hemodia 2020.Verification Test Report – Response Time Shaver Activation & Deactivation. Internal Report. HP3-RAP-051-B.
- Smith+Nephew 2020. Arthroscope Resolution Comparison Tech Report. Internal Report. 15010420 Rev A.
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
*DOUBLEFLO Pump is manufactured by Hemodia FRANCE and is distributed by Smith+Nephew, Inc. Sports Medicine.
**DOUBLEFLO is CE mark approved and pending 510K clearance
***LENS 4.0 App is CE mark approved and pending 510K clearance
****4KO laparoscopes pending CE mark